This is interesting based on clinical outcome data, which clearly demonstrates that FLT3-ITD-mutant AML with a co-existing NPM1 mutations have a more favourable prognosis that those with FLT3-ITD mutations and wild-type NPM1. The gene discussed is NPM1; the disease is acute myeloid leukemia.